CytoMed Therapeutics has obtained board approval to launch, subject to certain terms and conditions, a pilot program to isolate and cryo-store peripheral blood mononuclear cell for and as a reward to loyal shareholders of CytoMed on a complimentary basis. This Program is in line with the company’s strategy to build up a private bank of PBMC donors to develop allogeneic off-the-shelf cellular therapies using pre-qualified healthy donor blood. This Program will commence on June 1, 2024, or at such other date as CytoMed shall provide. Interested shareholders are advised to refer to CytoMed’s website for any future updates regarding the Program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDTC:
- CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
- Cytomed enters research collaboration agreement with Sengkang General Hospital
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
- Cytomed granted Malaysian patent for CAR-gamma delta T cell technology
- Malaysian Patent Granted for CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology
